𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma

✍ Scribed by Miyao, Kotaro; Sakemura, Reona; Imai, Kanae; Sakai, Toshiyasu; Tsushita, Natsuko; Kato, Tomonori; Niimi, Keiko; Ono, Yoshitaka; Sawa, Masashi

Book ID
125379044
Publisher
Carden Jennings Publishing
Year
2014
Tongue
English
Weight
484 KB
Volume
100
Category
Article
ISSN
0925-5710

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cyclophosphamide plus dexamethasone is a
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone
✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 153 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame